Navigation Links
Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb

SEATTLE, May 9, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. 


Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response. The immunoSEQ assay uses high throughput next-generation sequencing to characterize the repertoire of T and B cell receptors.  Application of this technology is being explored in cells of cancer patients, to assess the impact of treatments on the immune system and evaluated as a tool to identify patient populations who might be more likely to respond to targeted therapies based on their immune status.

"We are delighted to collaborate with Bristol-Myers Squibb to help uncover immunological biomarkers of response to cancer agents," said Chad Robins , CEO and Founder of Adaptive Biotechnologies.  "Collaborating with Bristol-Myers Squibb is a real win for companies like ours that are committed to deepening the understanding of the interaction between the host immune system and the cancer cells themselves."

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (, headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company's core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research and clinical communities as well as the biopharmaceutical industry. Adaptive operates a state-of-the-art high throughput centralized laboratory in Seattle that is CLIA certified and will be accepting clinical samples in 2013. Its flagship commercial product, immunoSEQ (, uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system's defense against disease – with unprecedented depth and specificity. In 2013, the company will introduce clonoSEQ (, a clinical assay to measure and monitor minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today's most common tests. All of Adaptive Biotechnologies' assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface.

SOURCE Adaptive Biotechnologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
2. TriLink BioTechnologies Awards Keck Science Department ResearchReward
3. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
4. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
5. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
6. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
7. Vestiage Signs Buyside Engagement Agreement with CJK Securities
8. Vertilon Signs Crisel Instruments as its Distributor in Italy
9. Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine
10. Entertainment Agency and Speaker Bureau Mark Sonder Productions Signs the Health & Wellness Shaman, Robert Cohen, PhD, LPC, DCEP for Meetings and Events Worldwide
11. Samsung Thales signs Development Agreement with Novelda
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
Breaking Biology Technology:
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
Breaking Biology News(10 mins):